

Indonesia Support for Human Papillomavirus Vaccine (HPV) Demonstration Programme

This Decision Letter sets out the Programme Terms of a Programme.

| 1. | Country: Indonesia | | | | | | | | | | | | | | | | |
|--------------------------------------|---|--------------------|--------------------|------|--------------------|---------------------|------------|------------|-------------|-----------|-------------|------------|-------------|--------------------------------------|--------------------|--------------------|--------------------|
| 2. | Vaccines grant number: 1718-IDN-19b-X Cash support grant number: 1718-IDN-24a-Y | | | | | | | | | | | | | | | | |
| 3. | Date of Decision Letter: 12 th August 2016 | | | | | | | | | | | | | | | | |
| 4. | Date of the Partnership Framework Agreement: December 2014 | | | | | | | | | | | | | | | | |
| 5. | Programme title: HPV Demonstration Programme | | | | | | | | | | | | | | | | |
| 6. | Vaccine type: HPV | | | | | | | | | | | | | | | | |
| 7. | Preferred product presentation and formulation of vaccine: HPV Quadrivalent, 1 dose(s) per vial, LIQUID | | | | | | | | | | | | | | | | |
| 8. | Programme duration¹: 2017 - 2018 | | | | | | | | | | | | | | | | |
| 9. | <p>Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable):</p> <table border="1" style="width: 100%; border-collapse: collapse; margin: 10px 0;"> <thead> <tr> <th style="width: 25%;"></th> <th style="width: 25%;">2017</th> <th style="width: 25%;">2018</th> <th style="width: 25%;">Total²</th> </tr> </thead> <tbody> <tr> <td>HPV vaccines (US\$)</td> <td style="text-align: right;">US\$97,500</td> <td style="text-align: right;">US\$83,000</td> <td style="text-align: right;">US\$180,500</td> </tr> <tr> <td>Cash (\$)</td> <td style="text-align: right;">US\$170,000</td> <td style="text-align: right;">US\$25,000</td> <td style="text-align: right;">US\$195,000</td> </tr> <tr> <td>Total programme Budget (US\$)</td> <td style="text-align: right;">US\$267,500</td> <td style="text-align: right;">US\$108,000</td> <td style="text-align: right;">US\$375,500</td> </tr> </tbody> </table> | | 2017 | 2018 | Total ² | HPV vaccines (US\$) | US\$97,500 | US\$83,000 | US\$180,500 | Cash (\$) | US\$170,000 | US\$25,000 | US\$195,000 | Total programme Budget (US\$) | US\$267,500 | US\$108,000 | US\$375,500 |
| | 2017 | 2018 | Total ² | | | | | | | | | | | | | | |
| HPV vaccines (US\$) | US\$97,500 | US\$83,000 | US\$180,500 | | | | | | | | | | | | | | |
| Cash (\$) | US\$170,000 | US\$25,000 | US\$195,000 | | | | | | | | | | | | | | |
| Total programme Budget (US\$) | US\$267,500 | US\$108,000 | US\$375,500 | | | | | | | | | | | | | | |
| 10. | Vaccine introduction grant: Not applicable | | | | | | | | | | | | | | | | |

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable)³

Vaccines:

| Type of supplies to be purchased with Gavi funds in each year | 2017 |
|---|------------|
| Number of HPV vaccines doses | 20,800 |
| Number of AD syringes | 21,900 |
| Number of safety boxes | 250 |
| Annual Amounts (US\$) | US\$97,500 |

Cash support:

| Cash support by year | 2017 |
|-----------------------|-------------|
| Annual Amounts (US\$) | US\$170,000 |

12. Procurement agency: UNICEF

13. Self-procurement: Not applicable

14. Co-financing obligations: Not applicable

15. Operational support for campaigns: Not applicable

³ This is the amount that Gavi has approved.

16. Documents to be delivered for future disbursements: The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future annual amounts. Further details can be found in the HPV application guidelines.


| Reports, documents and other deliverables | Due dates |
|--|---|
| <ol style="list-style-type: none"> 1. A copy of the approval by the local ethics committee, <i>if a country determined that review and approval was required.</i> 2. Three evaluation reports of the HPV vaccination demonstration programme: <ol style="list-style-type: none"> a. Post Introduction Evaluation (PIE) b. Coverage survey c. Costing analysis 3. A report of the assessment of adolescent health interventions, with conclusions about what interventions would be feasible for integration in year 2. <ol style="list-style-type: none"> a. If an adolescent health intervention is identified for joint delivery with HPV vaccine, the report should describe the identified intervention, the modified plans for Year 2, and the steps required for implementation with the district(s) and staff involved. b. If NO adolescent health intervention is identified for joint delivery with HPV vaccine the report should mention the reason why not. 4. A summary of the activities completed and progress towards the development of a national cervical cancer prevention and control strategy. | <p>As soon as they become available, and at the latest by end of year 1 (the first year starts when the first dose of vaccine is administered, and continues for 12 months)</p> |
| <ol style="list-style-type: none"> 5. A financial and activity report of expenditures by the end of year 1. | <p>End of year 1 (the first year starts when the first dose of vaccine is administered, and continues for 12 months)</p> |
| <ol style="list-style-type: none"> 1. If an adolescent health intervention is identified for joint delivery with HPV vaccine OR if the country substantially changed their delivery strategy: <ol style="list-style-type: none"> a. A new survey to measure the coverage of HPV vaccination and the coverage of the jointly delivered health intervention(s) and b. An updated micro-costing analysis of programme delivery costs. (Annex B) 2. If NO adolescent health intervention is identified for joint delivery with HPV vaccine in Year 2: A summary report of year 2 delivery of HPV vaccinations 3. A financial and activity report of expenditures in year 2. 4. A copy of the developed or revised national cervical cancer prevention and control strategy. | <p>End of Year 2 (the second year starts when the first dose of vaccine is administered to a new cohort, which is usually 12 months after the start of Year 1 and continues for twelve calendar months)</p> |

17. Financial clarifications: Country shall provide the following clarifications to Gavi*:

**Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements*

18. Other conditions: The country is reminded of its obligations under the PFA in respect of insurance and is requested to provide information to Gavi on the steps it has taken in this regard.

Signed by,



On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

12th August, 2016